An observational study in Heart Failure With Preserved Ejection Fraction, sponsored by Haiyan Wang. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-09.
Sponsored by Haiyan Wang · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 377 studies in Heart Failure with a site in China — 162 open to participants now, 182 under way, 18 of them phase 3. Heart Failure · China.
Among the 377 studies in Heart Failure with a site in China, this one is the 73rd largest by planned enrollment of the 130 observational ones that give a count, is one of 43 that started in 2023, is one of 130 observational ones, reaches primary completion later than 80 of the 181 other live ones, and was the 231st registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →162 of the 377 studies in Heart Failure with a site in China are open now. Recruiting first, the newest first:
Second Affiliated Hospital, Zhejiang University, School of Medicine · Sites in China
Ages 65+
Jiangsu Taizhou People's Hospital · Sites in China
Ages 65+ · Healthy volunteers
AstraZeneca · Sites in China, United States, Argentina and 29 more countries
Ages 18+
Pulnovo Medical, Inc. · Sites in China, United States
Ages 18–85
Tasly Pharmaceutical Group Co., Ltd · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
377 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 31 · Phase 2 44 · Phase 3 49 · Phase 4 30
First in 1983; this study’s year is marked. 43 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 438 is above the median of 200 across 1,987 observational studies indexed under Heart Failure.
Median enrollment 130 across the 247 interventional studies, 554 across the 130 observational. Of the 117 that completed or were terminated, 33 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
109 of 377 have an industry lead sponsor. The 10 most frequent:
Haiyan Wang is the lead sponsor of 5 studies on the registry; 2 are open to participants now.
Haiyan Wang has 1 study filed under Heart Failure — fewer than ten, so there is no comparison to draw.
47 of the studies in Heart Failure with a site in China that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06307652Phase 3AstraZenecaStudy to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | 2027-04-16 |
| NCT07496372Phase 3HELP Therapeutics Co., Ltd.A Pivotal Clinical Trial of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes Injection (HiCM-188) for the Treatment of Advanced Heart Failure(NYHA III-IV) | 2027-06-30 |
| NCT06736574Phase 3CytokineticsStudy With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction | 2027-09 |
| NCT06024746Phase 3Colorado Prevention CenterA Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF) | 2027-11 |
| NCT06927440Shanghai Jiao Tong University School of MedicineNational Multicenter Registry for Pediatric End-Stage Heart Failure in China | 2026-11-30 |
Add all 47 to your calendar (.ics) → With an account.
Among the 377 studies in Heart Failure with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to evaluating myocardial stiffness in patients with heart failure with preserved ejection fraction (HFpEF) by intrinsic wave velocity propagation (IVP). The main questions it aims to answer are:
Participants will undergo transthoracic echocardiography to obtain conventional ultrasound parameters, and software post-processing analysis to obtained two-dimensional strain parameters and IVP, as well as general clinical data and laboratory test results. Clinical followed up was performed through electronic medical records or telephone interviews until patient rehospitalization for heart failure or discharge for one year.
The included patients who diagnosed with HFpEF and healthy volunteers at the First Affiliated Hospital of Shandong First Medical University from December 20, 2023 to December 20, 2026. Routine clinical and echocardiographic data, two-dimensional strain parameters and IVP of the study subjects were obtained:
Patients who diagnosed with HFpEF according to the 2022 AHA/ACC/HFSA Guidelines for Heart Failure Management.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Meet the diagnostic criteria for HFpEF in the 2022 AHA/ACC/HFSA Guidelines for Heart Failure Management:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients who diagnosed with heart failure with preserved ejection fraction based on symptoms, serum biomarker and test according to 2022 AHA/ACC/HFSA Guidelines for Heart Failure Management at the First Affiliated Hospital of Shandong First Medical University from December 20, 2023 to December 20, 2026.
Diagnostic Test: Echocardiography examination
Healthy volunteers with no history of heart disease who matched for age, sex, and risk factors with HFpEF group.
Diagnostic Test: Echocardiography examination
Echocardiography examination and software post-processing analysis was performed to obtain parameters of conventional echocardiography, left atrial and left ventricle strain, and IVP.
IVP
The propagating wave velocity along longitudinal tissue motion direction is referred to as the Intrinsic Velocity Propagation (IVP). It is generated through the dynamic nature of the heart and allows quantification in all LV segments. It is possible that this wave is related to tissue stiffness and has a radial component.
Time frame: After recruiting, IVP collected through software post-processing analysis will be assessed and reported up to 8 weeks.
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2023 (actual). Primary completion is estimated for Dec 2026, 36 months after the start.
Of 799 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 100. This study's planned 36 months is below that.
Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Haiyan Wang